Healthcare
Live Price
Offline$22.84
-1.30% today
1Y Change
+85.42%
Window
Jun 20, 2025 → Jun 17, 2026
Coverage: 249 bars · Jun 20, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zymeworks Inc. (ZYME) is a Healthcare stock with a market cap of $1.99B and listed on NASDAQ. The stock last traded around $22.84 and up 85.4% across the available one-year price window (Jun 20, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +38.9%, EPS growth of +33.3%, a dividend yield of 0.0%. What stands out right now is revenue +38.9%, EPS +33.3%, free cash flow +69.5% with operating margin -87.3% and ROIC -30.1%. Valuation already assumes a fairly strong business story at price/sales 18.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ZYME price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZYME
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZYME Max Drawdown
-21.25%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZYME and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$26.7M
-93.5% YoY
FY Net Income
-$211.8M
-270.4% YoY
Free Cash Flow
-$205.7M
-257.1% YoY
Revenue Growth
+38.9%
EPS Growth
+33.3%
Gross Margin
98.4%
Net Margin
-76.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 106M | 76M | 76M | 412M | 27M |
| Gross Profit | 95M | 76M | -67M | 412M | 27M |
| Operating Income | -93M | -137M | -138M | 131M | -216M |
| EBITDA | 7.6B | -109M | -121M | 142M | -206M |
| Net Income | -81M | -123M | -119M | 124M | -212M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 41M | 66M | 158M | 401M | 202M |
| Total Assets | 347M | 463M | 581M | 649M | 389M |
| Total Liabilities | 78M | 124M | 116M | 156M | 140M |
| Shareholder Equity | 269M | 339M | 465M | 493M | 249M |
| Total Debt | 18M | 19M | 27M | 28M | 32M |
| Net Debt | -23M | -48M | -131M | -373M | -170M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
192M
-233.5% YoY
Capital Expenditures
13M
-1.2% YoY
Free Cash Flow
206M
-257.1% YoY
Key ratios
Gross Margin
98.4%
Operating Margin
-87.3%
Net Margin
-76.6%
ROE
-26.0%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.